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ABSTRACT
Genetic hemochromatosis is not a rare
disease and rep resents a fre q u e n t ly
u n d e re s t i m ated cause of art h ro p at hy.
Joint involvement is one of the most fre -
quent manifestations of the disease and
presents typical clinical and radiologi -
cal features that strongly suggest the
diagnosis. Joint complaints are often
the first clinical manifestation of GH.
Their identification may be crucial to
establish the diagnosis in the pre-cir -
rhotic phase and to institute appropri -
ate therapy to prevent organ damage
and associated mortality. Recent iden -
tification of the genetic defect responsi -
ble for the disease is leading to new in -
sights into the pathogenesis of GH and
the associated arthropathy.
Introduction
Classic genetic hemochromatosis (GH)
is an iron storage disease with a reces-
sive autosomal genetic transmission. It
results from the inap p ro p ri at e ly high
intestinal ab s o rption of iron and the
subsequent deposition of this metal in
several organs, eventually resulting in
o rgan lesions and functional insuffi-
ciency. Classically, GH is characterized
by the triad of liver cirrhosis, diabetes
mellitus and skin hy p e rp i g m e n t at i o n .
Arthropathy was recognized as a mani-
festation of GH only in 1964 (1), al-
most one hundred years after the first
d e s c riptions of the condition. Neve r-
theless, it is one of the most common
manifestations of the disease and the
most detrimental to the patient’s quali-
ty of life. The arthropathy of GH pre-
sents several characteristic clinical and




GH is one of the most common genetic
anomalies among the Caucasian popu-
lation, in whom more than 0.3% are
h o m o z y gous and 10% are hetero z y-
gous for the disease (2). GH is charac-
terized by excessive iron deposition in
parenchymatous cells, especially in the
liver, pancreas and heart. Accumulated
iron is held to be responsible for the
cellular lesions, although the ex a c t
m e chanisms invo l ved remain un-
known.
Duodenal iron absorption is augmented
in excess of 4 times the normal rate.
Clinical expression of the disease is 5
to 10 times more frequent in males than
in females, probably due to the protec-
tive effect of iron loss associated with
menstrual menses and pregnancy. The
first symptoms develop in almost 70%
of patients between the ages of 40 and
60 years (2).
Pathogenesis
In 1996, Feder described the HFE
gene, which has been demonstrated to
be responsible for the majority of cases
of GH in the Caucasian population (3).
This gene is incorporated in the class I
major histocompatibility complex
(MHC I), and localizes very close to
HLA-A. The HFE protein is expressed
on the cell surface, where it associates
to the transferrin receptor, reducing its
affinity by 5 to 10 times and thus de-
creasing the amount of transferrin that
e n t e rs the cell (4). In the Euro p e a n
population, between 60-100% of all pa-
tients with GH are homozygous for a
punctual mutation in this gene, consis-
ting of a substitution of cystein in posi-
tion 282 by tirosin (C282Y) (5). As a
result of this mu t at i o n , t h e re is no
expression of HFE on the cell surface,
the transferrin receptor is not inhibited
and an excessive amount of transferrin
enters the cell (6).
Another mutation of HFE, the H63D
mutation, has been described as com-
mon in the general population. On its
own, this mutation does not seem to
determine iron loading. However, com-
pound hetero z y gote patients (C282Y
and H63D) may develop considerable
iron storage and even clinical hemo-
chromatosis (7). Furthermore, several
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studies of linkage disequilibrium sug-
gest that the ability of the C282Y muta-
tion to induce iron loading can be
modulated by a number of other genes,
yet to be identified (8). These addition-
al genetic factors may contribute to the
variability of the disease’s clinical ex-
pression.
The integration of the HFE gene within
MHC I suggests a link between the
immune system and iron metabolism.
In fact, there is evidence that patients
with GH may present several immuno-
l ogical ab n o rmalities. A considerabl e
p ro p o rtion present ab n o rm a l ly low
numbers of CD8+ T lymphocytes and
raised CD4:CD8 ratios. These changes
are related to a higher accumulation of
iron (9, 10). The CD4:CD8 ratio has
even been proposed as a good indicator
of the clinical course of the disease (9).
It is interesting to note that these chan-
ges in peripheral lymphocytes remain
unchanged after efficient treatment of
the disease, suggesting that they are not
a consequence of iron overloading (9).
It has also been demonstrated that a
mouse strain which does not express
MHC I antigens, and therefore does not
have CD8+ lymphocytes, spontaneous-
ly develops iron overload on hepato-
cytes and, in addition, presents changes
in iron hemostasis similar to those
found in human GH (11, 12). Several
functional abnormalities on CD8+ lym-
p h o cytes have been described in pa-
tients with GH, and these are positively
c o rre l ated with the development of
l iver cirrosis (13-15). These observa-
tions support the hypothesis that the
i m mu n o l ogical ch a n ges associat e d
with GH may actually modulate iron
deposition and the clinical expression
of the disease.
Clinical aspects
The clinical manife s t ations of GH
i n clude skin hy p e rp i g m e n t at i o n , d i a-
betes mellitus, liver and heart dysfunc-
t i o n , a rt h ro p at hy and hy p ogo n a d i s m .
Liver involvement may initially show
up only in the form of hepatomegaly or
m o d e rate ch a n ges in liver enzymes.
With time, however, the condition pro-
gresses to liver dysfunction and cirrho-
sis. Hepatocellular carcinoma becomes
a complication in about 30% of patients
with liver cirrhosis (2). Skin hy p e r-
pigmentation is due to the deposition of
melanin and is usually ge n e ra l i ze d.
Heart involvement results in heart fail-
ure and arrhythmias. Hypogonadism is
due to low levels of go n o d o t ro p i n s ,
resulting from an iron overload in the
hy p o p hysis. Osteoporosis has been
described in 25 to 50% of cases, usual-
ly associated with hypogonadism (16).
The association of the typical clinical
manifestations suggests the diagnosis.
H oweve r, nu m e rous patients do not
p resent the classical triad of hep at o-
m ega ly, d i abetes and hy p e rp i g m e n t a-
tion. In fact, in a review of 93 patients,
only 8% presented the classical triad at
the time of diagnosis (17).
The phenotypical expression of GH is
highly variable, depending on the or-
gans involved in each patient and the
severity of the dysfunction. While some
patients develop a particularly severe
form of the disease with multiple organ
fa i l u re, some homozygous subjects
may never develop clinical disease (2,
18).
The combined determination of serum
fe rritin and tra n s fe rrin sat u ration re-
mains the most simple and re l i abl e
screening method for GH (19), even in
the asymptomatic phase. In homozy-
gous patients, transferrin saturation is
e l evated quite early in life - usually
higher than 50% in females and 60% in
males. Serum ferritin is a good indica-
tor of the total body iron load and is
ge n e ra l ly quite elevat e d. A defi n i t e
diagnosis can be established in two dif-
fe rent way s : (1) genetic typing (al-
though not all patients present the
known HFE mutations), and (2) liver
biopsy, which allows a definite diagno-
sis if iron overloaded hepatocytes can
be demonstrated, with a liver iron index
higher than 1.9. Liver biopsy has the
additional advantage of allowing evalu-
ation of tissue damage. The iron index
is calculated by dividing the concentra-
tion of iron in the dried liver fragment
(expressed in micrograms/ 100 ml) by
age.
Treatment is based on the removal of
ex c e s s ive iron through phleb o t o m i e s
and symptomatic management of any
organ dysfunction. Each 500 ml phle-
botomy contains 200 to 250 mg of iron.
They are repeated, once a week at the
start, until the saturation of transferrin
and serum ferritin fall below 50% and
50 g/l, respectively. Even then, it is
i n d i s p e n s able to rep e at the phleb o t o-
mies as needed, u s u a l ly eve ry 3
months, in order to avoid the re-accu-
mulation of iron (2).
The main causes of death in the ab-
sence of tre atment are heart fa i l u re,
liver cirrhosis and hepatocellular carci-
noma. Life expectancy for symptoma-
tic patients re c e iving adequate tre at-
ment is in the range of 90% at 5 years.
The removal of excessive iron can ame-
liorate the liver, heart and pancreatic
lesions and prevent hepatocellular car-
cinoma, but has no effect upon hypo-
gonadism or arthropathy once these are
established. Early diagnosis is, there-
fo re, essential and screening of the
patient’s relatives is mandatory (2).
The arthropathy of genetic 
hemochromatosis
Clinical aspects
Hemochromatosis arthropathy tends to
start at the small joints of the hands,
with special emphasis on the second
and third MCP joints. The first symp-
toms are arthralgias emerging after pro-
l o n ged exe rc i s e, p rogre s s ive stiff n e s s
and restriction of MCP flexion. With
time, the deformity of these joints be-
comes ap p a rent and the art h ro p at hy
extends to involve the proximal inter-
phalangeals and wrists as well (Fig. 1).
In many pat i e n t s , joint invo l ve m e n t
becomes more widespread, extending
to the elbows, shoulders, hips, knees,
ankles and the spine, not rarely result-
ing in considerable disability requiring
intensive rehabilitation and surgery. 
At the other ex t reme of the cl i n i c a l
s p e c t ru m , p atients may have only
moderate arthralgia, predominantly at
night and early in the morning (20-24).
In some cases, episodes of acute syn-
ovitis may occur, probably due to the
d eposition of calcium py ro p h o s p h at e
d i hy d rate crystals (pseudogout) (25).
On clinical grounds, the arthropathy of
h e m o ch ro m atosis may there fo re be
mistaken for osteoarthritis, primary cal-
cium pyrophosphate dihydrate (CPPD)
deposition arthropathy or even rheuma-
toid arthritis (26).
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Radiology
On radiological examination, GH arth-
ropathy may superficially resemble ost-
eoarthritis, based on the common fea-
tures of joint space loss, subchondral
cy s t s , s cl e rosis and osteophy t o s i s .
Some typical aspects may also suggest
primary CPPD disease, given that the
two conditions share several character-
istics: (1) involvement of joints usually
s p a red by osteoart h ri t i s , s u ch as the
MCP, wrists, elbows and shoulders; (2)
the presence of large subchondral cysts;
(3) uniform loss of joint space, contrary
to the asymmetrical distribution of this
feature in osteoarthritis; and (4) the fre-
quent association of chondrocalcinosis,
which may involve the knees, wrists,
pubic sinfi s i s , i n t e rve rt eb ral discs,
shoulders and hips (27).
Despite this, GH arthropathy presents
several radiological features that may
be considered as characteristic or even
specific (27), thus allowing the differ-
ential diagnosis from CPPD:
- preferential involvement of the MCP
j o i n t s , e s p e c i a l ly the second and
t h i rd, with more pronounced joint
space loss which may also involve
the fourth and fifth MCP (Fig. 2); 
- ve ry typical, h o o k - s h aped osteo-
phytes, in particular emerging from
the radial sides of the metacarpal dis-
tal epiphisis (Fig. 3). Similar osteo-
phytes may also be observed in other
affected joints, such as the elbows,
shoulders and hips; 
- diffuse involvement of the wrist but
with a lower prevalence of scapho-
lunar dissociation and ra d i o c a rp a l
involvement; and 
- in the hip it is occasionally possible
to identify a radiolucent zone in the
subchondral area of the femural head,
a finding that has been considered to
be specific for GH arthropathy (23-
25, 27-29).
H oweve r, most patients with GH
arthropathy do not present the typical
features described above, making the
disease indistinguishable, if based sole-
ly on clinical and radiological grounds,
from CPPD or even osteoarthritis (30,
31). In addition, a metacarpophalangeal
a rt h ro p at hy similar to GH has been
described in some patients with type II
d i abetes mellitus and has also been
a s s o c i ated with intense manual wo rk
(32, 33) (Fig. 4).
Pathogenesis
The pathogenesis of GH arthropathy re-
mains unknown. It is very tempting to
assume that iron overload is responsi-
ble for the joint disease. In fact, ex-
cessive iron deposits have been demon-
s t rated in the synovial membrane of
patients with this condition (34). Iron
salts have been shown to promote the
nu cl e ation of calcium py ro p h o s p h at e
crystals and inhibit its removal from the
joints (35-37), thus supporting a role
for iron in the development of chon-
drocalcinosis and pseudogout. Howev-
e r, the iron deposits and calcium
py ro p h o s p h ate crystals found in the
synovium of GH patients are not spa-
t i a l ly re l ated (38). Furt h e rm o re, n o
h e m o s s i d e rin has been found in the
fibrocartilage and hyaline cartilage of
these patients.
It is important to recognize that many
patients with GH do not develop joint
disease and that, in those who do, there
is no correlation between the extent of
the iron deposits and the radiological
and pathological findings in the joints
(24). Furthermore, GH treatment does
not ameliorate the joint disease. Addi-
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Fig. 1. Hands of a 63-year-old patient with genetic hemochromatosis (GH). Note the prominent
swelling of the second and third MCP joints.
Fig. 2. Postero-anterior radiograph of the hands of the same patient with GH.
tional arguments against a pri m a ry
pathogenetic role for iron is given by
the observation that excessive iron de-
posits in the synovium are also found in
rheumatoid arthritis, osteoarthritis, pig-
mented villonodular synov i t i s , h e m o-
philia, hemarthrosis and acquired he-
m o c ro m at o s i s , although the joint in-
volvement in these conditions is quite
dissimilar to that seen in GH (24, 39-
41). Interestingly, juvenile GH, which
is not associated with the HFE gene
mutation, does not present arthropathy.
All of these observations strongly sug-
gest that other fa c t o rs besides iro n
deposition may be responsible for the
arthropathy associated with adult GH.
One possibility is that joint invo l ve-
ment derives from a different metabolic
defect, which accompanies but is inde-
pendent from iron metabolism. A
disturbance of parat hy roid horm o n e
(PTH), consisting in the elevation of
the serum concentration of PTH frag-
m e n t s , has been suggested to play a
role, but studies on this subject have not
yielded conclusive results (42).
Another possibility is that the develop-
ment of the arthropathy depends on the
presence of genes that modify or modu-
l ate the clinical ex p ression of the
C282Y mutation in HFE (8).
It has also been suggested that the
immunological abnormalities associat-
ed with GH may be responsible for the
d evelopment of art h ro p at hy in some
patients, in the same way as they seem
to modulate the degree of iron overload
and susceptibility to liver cirrhosis (9-
15).
Prevalence of arthropathy in genetic
hemochromatosis
Arthropathy is one of the most common
manifestations of GH, affecting 28 to
81% of all patients, depending on the
study (17, 25, 30, 31, 42-45). Further-
more, 31 to 60% of all patients with GH
p resent an art h ro p at hy with typical
radiological features, particularly in the
MCPs (17, 25, 30, 31, 42). The preva-
lence of chondrocalcinosis is lower, as
it is present in 3.8 to 38% of patients
(17, 30, 31, 42). Episodes of acute syn-
ovitis (pseudogout) seem to be relative-
ly rare (22, 31, 44). 
The average age of patients with arthro-
p at hy at diagnosis is in most seri e s
higher than the age of those without
joint involvement. On the other hand,
arthralgias are the most frequent and
the longest lasting manifestations of the
disease (17, 31). This is in clear con-
trast with the previous clinical concept
of GH wh i ch undere s t i m ated art h-
ro p at hy, and underlines the need to
consider the possibility of this disease
when faced with a compatible pattern
of joint involvement.
P re s e n t ly, GH is fre q u e n t ly detected
and treated in the early phases of the
disease, making it rare to have the clas-
sical clinical triad (17). In addition, as
progression of arthropathy is not modi-
fied by tre at m e n t , joint invo l ve m e n t
will become an even more important
aspect of genetic hemochromatosis.
This arthropathy may be extremely dis-
abl i n g, and fre q u e n t ly re q u i res joint
prosthesis (46). Adams et al. evaluated
the impact of the diverse clinical mani-
festations of GH on the quality of life
of 50 patients and concluded that arth-
ropathy has the largest functional im-
pact, although cirrhosis is the most im-
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Fig. 3. Close-up of the same patient’s right hand, showing hook-shaped osteophytes on the second and
third metacarpal heads.
Fig. 4. Radiograph of the hands of a 68-year-old patient. The radiological features of the MCPs are
similar to GH arthropathy, but the patient does not have hemochromatosis or diabetes mellitus. He
worked in a profession that required heavy manual labour.
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portant factor in mortality (47).
In conclusion, GH arthropathy presents
typical clinical and ra d i o l ogical fe a-
tures that should suggest the diagnosis,
rep resents one of the most fre q u e n t
manifestations of the disease and has a
major functional impact on the quality
of life. Its pat h ogenesis may not be
d i re c t ly re l ated to iron ove rl o a d, bu t
may be linked with metabolic and im-
munological abnormalities induced by
the HFE gene mutation or associated
genes. A rt h ro p at hy is fre q u e n t ly the
first clinical manifestation of GH, al-
lowing the diagnosis to be established
in the pre-cirrhotic phase and therefore
a l l owing the prevention of organ in-
volvement and associated mortality.
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